Mentioned On
Episode Mentions
Pharma and BioTech Daily · Apr 29, 2026
AstraZeneca's Breztri Asthma Approval Boosts $80B Goal | Pharma and Biotech Daily
“Strategic move into KRAS inhibition through $1.45 billion BioBux deal with Kestrel Therapeutics”
FDA Drug Approval and RescissionData Integrity in Drug DevelopmentAI-Designed Therapeutics
View Analysis